Clinical Trials Directory

Trials / Completed

CompletedNCT05161676

Metabolic Effects of Chronic Ketosis (KETO-CHF Metabolic)

Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Metabolic Effects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
12 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Heart Failure (HF) is a major public health issue because the disease affects 1-2% of the Western population and the lifetime risk of HF is 20%. Despite major improvements in the management and care of patients with HF, the 1-year mortality in patients with HF is 13% and \>50% of HF patients are admitted during a 2.5 year period. Furthermore, patients with HF have markedly decreased physical capacity and quality of life. Thus, there is a need for new treatment modalities in this group of patients. It is well established that patients with heart failure have metabolic disturbances, including disturbed glucose metabolism with increasing insulin resistance, increased lipolysis, and disturbances in skeletal muscle homeostasis. Presently there are no data on the clinical metabolic effects of long-term oral ketone-supplementation in patients with chronic HF. In this study we aim to investigate the effect of 14 days modulation of circulating ketone body levels on endogenous protein, glucose, and fatty acid metabolism in patients with HFrEF.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKetone monoesterCommercially available ketone supplement
DIETARY_SUPPLEMENTPlacebo drinkIsocaloric placebo

Timeline

Start date
2021-12-15
Primary completion
2023-05-01
Completion
2023-10-01
First posted
2021-12-17
Last updated
2023-11-30

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05161676. Inclusion in this directory is not an endorsement.